What does sevabertinib-Hyrnuo treat?

Sevabertinib (sevabertinib)-Hyrnuo is a reversible tyrosine kinase inhibitor (TKI) specifically used to treat HER2-mutated non-small cell lung cancer (NSCLC) . According to the FDA's approval, the drug is suitable for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer, especially those whose tumors contain activating mutations of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase domain (TKD) and who have previously received systemic therapy.

Non-small cell lung cancer is the most common type of lung cancer, accounting for more than 85% of all lung cancer cases. In patients with advanced non-small cell lung cancer, activating HER2 mutations occur in 2% to 4%. Cervatinib in Hyrnuo inhibits the growth of cancer cells by effectively inhibiting mutant HER2 (including HER2 exon 20 insertions and HER2 point mutations) and epidermal growth factor receptor (EGFR). In addition, the drug is highly selective for mutant versus wild-type EGFR, making it more effective when targeting specific tumor types.

Hyrnuo is taken orally as a tablet twice daily with food until disease progression or unacceptable toxicity occurs. There are several warnings and precautions to be aware of when using Hyrnuo, including diarrhea, hepatotoxicity, interstitial lung disease (ILD) or pneumonia, ocular toxicity, elevated pancreatic enzymes, and embryo-fetal toxicity.

In clinical practice,the incidence rate of common adverse reactions of Hyrnuo exceeds 20%, including diarrhea, rash, paronychia, stomatitis and nausea. Monitoring and management of these adverse effects is critical to patient outcomes and quality of life. Therefore, when treating with Hyrnuo, patients and medical providers should maintain close communication in order to promptly identify and deal with possible side effects to ensure the safety and effectiveness of the treatment.

In general, sevabertinib provides a new treatment option for patients with HER2-mutant non-small cell lung cancer and shows good clinical application potential. Sevabertinib is also being studied in patients with metastatic or unresectable solid tumors containing HER2 activating mutations (panSOHO) (excluding advanced non-small cell lung cancer).

Reference materials:https://en.wikipedia.org/wiki/Sevabertinib